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KEY POINTS
 Monoclonal gammopathy of undetermined significance and multiple myeloma (MM) are
plasma cell disorders of advanced age.
 Unexplained anemia, hypercalcemia, renal insufficiency, or bone pain, among other
symptoms, should prompt a work-up for a plasma cell disorder.
 Chemotherapy is standard of care for MM and, although incurable, survival in MM is pro-
gressively improving thanks to new drugs.
 Treating MM in older adults requires careful monitoring, dosing, and management of
toxicity to attain good outcomes.
 Geriatric assessment and other novel instrumentsmay soon enable personalization of MM
therapy for older adults.INTRODUCTION AND EPIDEMIOLOGY
Monoclonal gammopathy of undetermined significance (MGUS) and multiple
myeloma (MM) are disorders on the spectrum of plasma cell dyscrasias that are dis-
eases of aging. In multiple population-based studies, the prevalence of MGUS in-
creases with age; 5.3% of people greater than or equal to 70 years old and 7.5% of
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Guerard & Tuchman192is 69 years, with half of deaths from MM occurring in patients aged 75 years and older
(Fig. 1).2 MM accounts for about 10% of all hematologic malignancies and 1.6% of all
new cancer cases in the United States.2,3 It is estimated that there will be 26,850 new
cases of MM in 2015. MGUS andMM are more common in men than in women, and in
African Americans than in white people.1,2,4,5
Five-year overall survival in MM has increased from 29.7% in 1990 to 45.1% in
2007,2 largely attributable to novel therapies.6
Given the anticipated growth in the older adult population and presumably static
prevalence rates as a function of age, the raw numbers of older adults with plasma
cell disorders will increase over time. Therefore, a familiarity with MM and MGUS is,
and will remain, important for geriatricians.BIOLOGY AND CAUSE
MM is a malignancy of plasma cells, terminally differentiated B lymphocytes that
secrete antibodies when exposed to specific antigens. The exact pathogenesis of
MM and MGUS is not well understood. Virtually all cases of MM are thought to arise
from MGUS, a premalignant, asymptomatic proliferation of plasma cells.7,8 The initia-
tion of MGUS is likely an abnormal plasma cell response to antigenic stimulation that
leads to primary cytogenetic abnormalities and other genomic changes; the resultant
derangement of plasma cell biology ultimately causes plasma cell clonal expansion
and in some cases clinically significant disease. The expanded plasma cells usually
overproduce a complete monoclonal immunoglobulin or some part thereof (eg, light
chain only).9,10 The transition in some cases from MGUS to MM is thought to be
caused by additional biological abnormalities (eg, genomic, bone marrow microenvi-
ronmental) that lead to further clonal proliferation.9 Once MGUS has progressed to
MM, end organ damage begins because of infiltration of the neoplastic plasma cells
into the bones and organ systems, damage mediated by circulating monoclonalFig. 1. Age distribution of patients with MM and deaths from MM. (Data from Institute NC.
SEER stat fact sheets: myeloma. 2015. Available at: http://seer.cancer.gov/statfacts/html/
mulmy.html. Accessed May 18, 2015.)
MGUS and MM in Older Adults 193proteins (eg, cast nephropathy), or both. Between MGUS and MM there is an interme-
diate phase, termed smoldering MM (SMM), which is not always identified before an
MM diagnosis. SMM constitutes a higher-burden disease state than MGUS, but one in
which end organ damage is similarly absent.
Risk factors such as radiation or pesticide exposure,11,12 or history of autoimmune
or chronic infectious disease,13 have been described as risk factors for MM or MGUS,
but most patients with MM and MGUS have no identifiable risk factors. Perhaps the
most important risk factor for these diseases is advanced age. A growing body of
research supports the link between aging and MM; as an example, serum levels of
the proinflammatory cytokine interleukin 6 (IL-6) increase as a function of age,14
and, in MM, plasma cells secrete IL-6 and overexpress the IL-6 receptor.15 In the
future, insights such as this are likely to elucidate deeper links between MM and aging
and potentially yield beneficial interventions for both conditions.CLINICAL PRESENTATION OF MULTIPLE MYELOMA
The clinical presentation of patients with MM is variable and can be subtle. The 2 case
presentations discussed here highlight this variability.
 Case 1. A 75-year-old woman with osteoporosis presented to the emergency
department after experiencing a fall followed by right hip pain. She reported fa-
tigue, poor appetite, and mild weight loss for the past 6 months. Radiographs
showed a pathologic fracture involving the distal femur. Intraoperative biopsy
showed clonal plasma cells, and complete skeletal radiographs showed diffuse
lytic bone lesions. Bone marrow biopsy also revealed clonal plasma cells, indi-
cating a diagnosis of MM.
 Case 2. An 80-year-old man with hypertension and mild cognitive impairment
presented to his geriatrician’s office for routine follow-up. His only complaint
was increased fatigue. Physical examination was nondiagnostic. Routine labora-
tory evaluation revealed normocytic anemia (hemoglobin level, 9.5 g/dL),
increased total protein level, and a mild increase in his creatinine level to
1.35 mg/dL. Serum protein electrophoresis (SPEP) and immunofixation revealed
a monoclonal spike of 2.5 g/dL immunoglobulin (Ig) G-kappa, and a bone marrow
aspirate and biopsy by a consulting hematologist showed 20% monoclonal
plasma cells, confirming MM.
The common findings seen in MM at diagnosis are shown in Table 1.16 The lack of
any clinical features that are frequently and uniquely present in MM can make this
diagnosis challenging. For example, anemia is present in 73% of patients with MM
but anemia is common in community-dwelling older adults and is more commonly
explained by nutritional deficiencies, anemia of chronic disease, or chronic kidney dis-
ease.17 Hypercalcemia is present in 28% of patients with a new diagnosis of MM but is
also commonly caused by thiazide diuretics or primary hyperparathyroidism. Fatigue,
which is common in MM, is seen in innumerable other medical conditions too. No
physical examination findings are reliably sensitive and specific for diagnosing MM.16EVALUATION AND DIAGNOSIS
Screening for MGUS and MM is not recommended for older adults.18 MGUS is highly
prevalent, progresses to MM in only a small percentage of patients,19 and there is no
known strategy to prevent that progression.18 Geriatricians should consider a diag-
nostic work-up for plasma cell disorders only when a reason to suspect one exists.
Table 1
Clinical features of MM
Clinical Feature Frequency (%)
History
Bone pain 58
Family history of cancer 42
Fatigue 32
Weight loss 24
Known history of MGUS 20
Physical Examination
Hepatomegaly 4
Splenomegaly 1
Lymphadenopathy 1
Laboratory
Anemia 73
Increased creatinine level 48
Increased calcium level 28
Leukopenia 20
Thrombocytopenia 5
Radiology
Lytic lesions 66
Pathologic fractures 26
Osteoporosis 23
Data from Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed mul-
tiple myeloma. Mayo Clin Proc 2003;78(1):21–33.
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work-up:
 Age-disproportionate osteoporosis or osteopenia
 Increased serum total protein level without increased serum albumin level
 Bone pain, lytic bone lesions, pathologic and/or compression fractures
 Unexplained peripheral neuropathy, hypercalcemia, anemia, proteinuria, or renal
insufficiency
The initial diagnostic work-up should include the following laboratory tests:
 SPEP and 24-hour urine protein electrophoresis (UPEP) with immunofixation
 Serum free light chains
 Complete blood count (CBC)
 Serum creatinine and calcium levels
 Quantitative immunoglobulins
The diagnostic criteria for MM, SMM, and MGUSwere recently updated (Box 1).20 If
a monoclonal protein is not detected on serum or urine studies, then MM is extremely
unlikely and most plasma cell diseases can usually be confidently excluded from
consideration; nonsecretory myeloma (ie, MM that does not secrete monoclonal pro-
tein) does exist but is rare.21 If a monoclonal protein is detected, then the patient
needs additional work-up to clarify the diagnosis. The first step is to determine
Box 1
2014 Revision of International Myeloma Working Group diagnostic criteria
MM
Clonal bone marrow plasma cells greater than or equal to 10%, or biopsy-proven bone, or
extramedullary plasmacytoma
Plus at least 1 myeloma-defining event.
Myeloma-defining events:
 Hypercalcemia
 Serum calcium level greater than 1 mg/dL higher than upper limit of normal or greater
than 11 mg/dL
 Renal insufficiency
 Creatinine clearance less than 40 mL/min or serum creatinine level greater than 2 mg/dL
 Anemia
 Hemoglobin level less than 10 g/dL or greater than 2 g/dL less than the lower limit of
normal
 Bone lesions
 One or more osteolytic lesions on skeletal survey, computed tomography (CT), or PET/CT
 Biomarkers of malignancy
 Clonal bone marrow plasma cells greater than or equal to 60%
 Involved/uninvolved serum free light chain ratio greater than 100 with involved light chain
greater than 10 g/dL
 Greater than 1 focal lesion on MRI
Smoldering MM
Both criteria must be present:
 Serum monoclonal protein (IgG or IgA) level greater than 3 g/dL, or urinary monoclonal
protein level greater than 500 mg per 24 hours, and/or clonal bone marrow plasma cells
10% to 60%
 No myeloma-defining events or evidence of amyloidosis
MGUS
All 3 criteria must be present:
 Serum monoclonal protein level less than 3 g/dL
 Bone marrow plasma cells less than 10%
 No myeloma-defining events or evidence of amyloidosis
Adapted from Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Work-
ing Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol
2014;15(12):e538–48.
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insufficiency, anemia, bone lesions, or biomarkers of malignancy (see Box 1). Next,
bone marrow aspiration and biopsy are indicated in patients with a myeloma-
defining event, a monoclonal protein level greater than 1.5 g/dL, a non-IgG mono-
clonal protein level of any amount, or abnormal free light chain ratio. In certain
patients, further studies, including complete skeletal radiographs, lactate dehydroge-
nase, albumin, and b2-microglobulin, should be considered. More sensitive imaging,
such as computed tomography (CT) or MRI, should be used as warranted by clinical
symptoms (eg, unexplained bone pain) to evaluate for lesions not detected by skeletal
radiographs.
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cancer, usually MM, is approximately 1% per year.19 There is no single prognostic
marker to determine which patients will progress, but a serum monoclonal protein
level of greater than 1.5 g/dL, a non-IgG monoclonal immunoglobulin, and abnormal
serum free light chain ratio are known risk factors for progression (Table 2).22,23
Because the risk of progression does not decrease over time, patients with MGUS
require lifelong monitoring. It has been suggested that patients with low-risk disease
can be monitored by history and physical (HP) only for signs or symptoms of disease
progression and do not necessarily need routine laboratory monitoring.24 All other risk
groups should be monitored with an HP and laboratory evaluation with an SPEP,
UPEP, CBC, creatinine level, and calcium level every 3 to 12 months, depending on
the individual and the characteristics of the plasma cell disease. Older patients with
a limited life expectancy (<5 years) do not need routine follow-up given that these pa-
tients are likely to die of other causes before MGUS progresses to MM. Older adults
with MGUS can be effectively monitored by their primary care physicians.
Unlike in MGUS, approximately half of patients with SMM progress to MM within
5 years and roughly 80% progress over 20 years.25 Risk factors for progression
include an abnormal serum free light chain ratio or both a serum monoclonal protein
level of greater than 3 g/dL and clonal bone marrow plasma cells of greater than
10% (only 1 is required to diagnose SMM).25 Patients with SMM should be monitored
at 2 to 3 months after the diagnosis and then every 4 to 6 months with an HP and lab-
oratory testing.25 There are several therapies currently under investigation to prevent
or delay progression to symptomatic MM,26 but standard of care in the United States
arguably remains observation. Medical oncologists and hematologists are often
involved in monitoring these higher-risk patients.
STAGING AND PROGNOSIS
The Durie-Salmon system was developed 40 years ago27 and incorporates multiple
known independent markers of prognosis (Box 2). Durie-Salmon still retains prog-
nostic capacity. In one comparative study of patients after transplantation for MM, pa-
tients who were Durie-Salmon stage 1 versus stage 3 had a median overall survival of
82 versus 50 months, respectively.28 More recently, the simpler International Staging
System (ISS) was developed (see Box 2).29 In the same study as described earlier, pa-
tients at ISS stage 1 versus 3 had overall survival of 64 and 45 months respectively.
Notably, no study has definitively shown either system to be superior to the other,
although ISS is used more commonly because of its simplicity. No large trial hasTable 2
Mayo Clinic risk stratification for progression of MGUS to MM
Risk Stratification Risk of Progression at 20 y (%)
High risk (3 risk factors) 58
High to intermediate risk (2 risk factors) 37
Low to intermediate risk (1 risk factor) 21
Low risk (0 risk factors) 5
Risk factors: serum monoclonal (M) protein level greater than 1.5 g/dL, non-IgG M-protein,
abnormal serum free light chain ratio.
Adapted from Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an inde-
pendent risk factor for progression in monoclonal gammopathy of undetermined significance.
Blood 2005;106(3):812–7.
Box 2
Prognostic systems in MM
Durie-Salmon staging system27
Stage 1
All of:
Hemoglobin level greater than 10 g/dL
Normal serum calcium level
Radiograph skeletal survey normal or showing solitary bone plasmacytoma or osteoporosis
Serum paraprotein level less than 5 g/dL if IgG, less than 3 g/dL if IgA
Urinary light chain excretion less than 4 g/24 h
Stage 2
Not stage 1 or 3
Stage 3
Any of:
Hemoglobin level less than 8.5 g/dL
Calcium level greater than 12 mg/dL
Skeletal survey with more than 2 lytic lesions
Serum paraprotein level greater than 7 g/dL if IgG, greater than 5 g/dL if IgA
Urinary light chain excretion greater than 12 g/24 h
Subclassification:
A: Serum creatinine level less than 2 mg/dL
B: Serum creatinine level greater than or equal to 2 mg/dL
International Staging System29
Stage 1
Serum b2-microglobulin level less than 3.5 mg/dL and serum albumin level greater than or
equal to 3.5 g/dL
Stage 2
Not stage 1 or 3
Stage 3
Serum b2-microglobulin level greater than or equal to 5.5 g/dL
Adapted fromDurie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation
of measured myeloma cell mass with presenting clinical features, response to treatment, and
survival. Cancer 1975;36(3):842–54; and Greipp PR, San Miguel J, Durie BG, et al. International
staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412–20.
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of patients in the original report describing ISS were more than 65 years old, support-
ing the ability to generalize ISS to older adults with MM.29 Molecular markers are also
highly prognostic in MM. Some, such as deletions of chromosome 17p (p53 gene), are
common in many forms of cancer, whereas others, such as gains of chromosome 1q
(CKS1B gene), are unique to MM. An extensive consensus discussion of molecular
prognostic markers in MM has been recently published.30
Age is a prognostic marker in MM, albeit a complex one. Multiple population-level
studies show that survival in older patients with MM is inferior to that of younger
patients, despite improvements over recent decades in all age groups.31–33 However,
it is unclear to what degree poorer survival in older adults is caused by differences in
Guerard & Tuchman198disease biology, inability to tolerate intensive therapy such as transplant, medical co-
morbidity, or simply natural death caused by advanced age. MM biology does not
seem to be distinctly different in younger versus older patients, in contrast with other
hematological malignancies such as acute myelogenous leukemia, in which advanced
age predicts high-risk biology.34 In MM, for example, a balanced translocation of chro-
mosomes 4 and 14, termed t(4;14), is a marker of poor prognosis that in one study was
less common in older patients,35 but in another report ISS stages with good prognosis
were also less common in older patients.36 Hence the scarce available data are con-
tradictory and further studies are needed to elucidate the interaction between age and
MM biology in more detail.MANAGEMENT AND TREATMENT
Treating MM in older adults can be affected by several factors that have little to do with
MM itself, such as medical comorbidity, polypharmacy, and frailty. This issue is critical
given that the intensity of MM therapy ranges from low-dose, single drugs intended to
achieve disease palliation and minimize toxicity, to high-dose chemotherapy with
autologous hematopoietic stem cell transplant (ASCT). Treating clinicians need to
carefully judge the capacity of each older adult to tolerate the different levels of inten-
sity of possible MM therapies. Overly generous assessments of a patient’s capacity to
tolerate therapy may result in overtreatment and excessive, even fatal, toxicity. Overly
conservative assessments could result in inadequately intensive therapy and
increased risk of poor disease response, early relapse, and disease-related morbidity
or mortality. Hence much of the focus in recent years has been on optimizing geriatric-
specific assessment techniques for predicting therapeutic toxicity, with the over-
arching goal of matching individual older adults with regimens of an intensity that
best controls MM without inducing serious harm.
The arguable gold standard for maximally intensive MM therapy is ASCT. Historical-
ly, age less than 65 years was the key determinant for ASCT candidacy, enforced
largely by lack of governmental insurance coverage for ASCT for patients more than
65 years old in Europe. Such policy limitations did not exist in the United States,
although strict age cutoffs were observed in most transplant centers.
More recently, physiologic age is increasingly recognized as superior to chronologic
age for assessing ASCT candidates. Several studies have shown that ASCT with
dose-reduced chemotherapy can be safe and efficacious in appropriately selected
older adults (usually those with limited comorbidities and good functional status),
with similar rates of severe toxicity, time until MM progression, and overall survival
compared with younger patients.37–39 In particular, fit patients in their early 70s are
now routinely offered ASCT with a safe expectation of good results.
A comprehensive discussion of drug regimens for the treatment of MM goes beyond
the scope of this article. However, a basic listing of some of the more common treat-
ment regimens for older adults with MM is shown in Table 3. The primary drug classes
include corticosteroids (dexamethasone or prednisone), conventional cytotoxic drugs
(primarily the alkylators cyclophosphamide andmelphalan), and newer drugs (ie, novel
agents). The 2 classes of novel agents approved for commercial use are proteasome
inhibitors (bortezomib and carfilzomib) and immunomodulatory agents (thalidomide,
lenalidomide, and pomalidomide). Even newer drugs in those therapeutic classes
are being developed, as are drugs from new classes, such as monoclonal antibodies.
At the time of writing, daratumumab (targets CD38) and elotuzumab (targets SLAMF7)
are examples of monoclonal antibodies currently under US Food and Drug Adminis-
tration (FDA) review for possible approval for treatment of relapsed and refractory MM.
Table 3
Common treatment regimens for older adults with MM
Initial Treatment Options
Relapsed/Refractory
Drug Optionsa
Transplant Eligible
 Bortezomib, lenalidomide,
dexamethasone
 Bortezomib, cyclophosphamide,
dexamethasone
 Bortezomib, dexamethasone
 Lenalidomide, dexamethasone
Transplant Ineligible
 Any regimen recommended
for transplant eligible
 Bortezomib, melphalan,
prednisone
 Melphalan, prednisone,
thalidomide
 Melphalan, prednisone,
lenalidomide
Immunomodulators
 Lenalidomide
 Pomalidomide
 Thalidomide
Proteasome inhibitors
 Bortezomib
 Carfilzomib
Alkylators
 Cyclophosphamide
 Melphalan
Other cytotoxics
 Doxorubicin (standard
or liposomal)
 Vincristine
 Bendamustine
Corticosteroids
 Dexamethasone
 Prednisone
a A combination of drugs is commonly used in the relapsed/refractory setting and the choice of
drug combinations is based on previous treatments’ efficacy and tolerability, patient-related fac-
tors, and perceived disease aggressiveness, among many other factors.
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be a suitable candidate for ASCT, other patient-related factors, and MM-specific fac-
tors, such as the presence of specific genetic abnormalities. However, the lines be-
tween regimens specifically for ASCT candidates versus noncandidates are blurring.
Historically, melphalan was a favorite among non-ASCT candidates but was avoided
in ASCT candidates because of melphalan’s hematopoietic stem cell toxicity and its
propensity to impair stem cell mobilization. More recently, melphalan’s usage has
decreased as other highly effective drugs have become available, resulting in less
firm distinction between regimens for these two cohorts of patients. Another important
point is that most of these regimens were not studied extensively in much older adults
and/or those with substantial comorbidities, so oncologists commonly reduce doses
and use alternative administration strategies based their assessment of each older
patient.
Further building on the concept that to some degree age is just a number, cancer-
specific geriatric assessment (GA) instruments have been developed that evaluate
older adults in a manner that uncovers problems not routinely identified by oncolo-
gists, predicts chemotherapy toxicity, and in the future may assist in therapy selection.
The Cancer and Aging Research Group (CARG) GA was developed for older patients
with cancer and contains valid and reliable measures of geriatric domains pertaining to
physical function, independent activities of daily living (IADLs), polypharmacy, medical
comorbidity, nutritional status, mental health, social support, and cognitive function.40
The CARG GA, which is mostly patient reported, was shown to predict chemotherapy
toxicity. High-risk versus low-risk patients identified by the CARG toxicity tool had an
89% versus 25% risk respectively of severe chemotherapy toxicity, in contrast with
provider-reported Karnofsky Performance Status, which did not predict toxicity.41
Another model, the Chemotherapy Risk Assessment Scale for High-Age Patients
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chemotherapy regimen–specific risk of toxicity and patient-specific predictors, such
as performance status, mini–nutritional assessment, and mini–mental health status.42
Clearly GA tools have great promise in MM, but an important caveat is that these GA
instruments have generally been tested in patients with solid tumors and their rele-
vance to MM has not been fully elucidated. Recently, a single larger study of older
adults with MM used a combination of age, the Charlson Comorbidity Index, and abil-
ity to perform IADLs to classify patients as frail, intermediate fitness, and fit. That
model predicted vital MM-specific outcomes: toxicity, discontinuation of therapy
within 12months, progression-free survival, and overall survival (Table 4).43 This study
serves as proof of principle of GA’s relevance to MM, but presumably more compre-
hensive GA instruments such as CARG or CRASH could even better classify at-risk
patients.
Observational studies are ongoing to test more comprehensive GA systems such as
the CARG GA directly in MM, and initial data are promising.44 The next challenge is to
incorporate GA-derived predictions of chemotherapy toxicity into decision-making
models for therapy selection in older adults with MM. If so, GA may someday provide
an avenue to match older MM patients with treatment regimens of appropriate inten-
sity, thereby maximizing the likelihood of MM control and avoiding overtreating or
undertreating and risking severe toxicity or inadequate efficacy respectively. Only
now are groups such as ours and others designing clinical trials that incorporate
some form of GA into eligibility criteria. Trials such as these that use GA to determine
treatment intensity may prepare the way to GA-based decision models for therapy se-
lection and allow prospective assessments of the effect a drug has on GA domains,
which are important and unique outcomes to older patients with cancer.
SIDE EFFECTS AND SUPPORTIVE CARE
Older adults are subject to the same toxicities that younger patients may experience
while undergoing therapy for MM, and, for the reasons discussed earlier, such as
reduced homeostatic reserve and medical comorbidities, therapy-related toxicities
can be more pronounced in older patients. Therefore, aggressive supportive care
andadeep familiaritywith the side effect profile ofMMtherapies andmanagement stra-
tegies are critical to successful therapy. Certain unique issues that stem from widely
used drugs in MM warrant mentioning when considering treatment of older adults.
Bortezomib (Velcade) is broadly used and FDA approved in both newly diagnosed
and relapsedMM,with data from large randomized trials showing prolonged remission
and overall survival.45,46 Common toxicities include sometimes severe gastrointestinalTable 4
International Myeloma Working Group GA and outcomes
GA Classification
Overall Survival (Hazard
Ratioa) P
Therapy Discontinuation
Within 12 mo (%) P
Fit 1 — 1 —
Intermediate fitness 1.37 .181 1.41 .52
Frail 2.88 <.001 2.21 <.001
a Adjusted for therapy, chromosomal abnormalities, and ISS stage.
Data from Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and
toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood
2015;125(13):2068–74.
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and orthostatic hypotension. Studies have shown that administering bortezomib
once weekly instead of twice weekly reduces gastrointestinal and neuropathic toxicity
by roughly 30%,47 and subcutaneous instead of intravenous administration similarly re-
duces toxicity.48 Neither modification detracts from bortezomib’s overall treatment ef-
ficacy, anddecisions about dosing are usually determinedby thepatient’s health status
and disease characteristics. Providers and nurses need to routinely assess side effects
and aggressively modify doses if such toxicity appears to a substantial degree.
Bortezomib-induced neuropathy can be reversible with dose modifications or cessa-
tion.49 Antimotility agents such as loperamide can control diarrhea. Patients who regu-
larly experience diarrhea after bortezomib can use antimotility agents preemptively
before diarrhea starts. In addition, paying close attention to hydration/volume status
and electrolytes is vital.
In the past, thalidomide was often used to treat MM and detailed discussions of
toxicity were required. Thalidomide commonly causes constipation, sedation, and pe-
ripheral neuropathy, which can be particularly problematic in older adults. Readily
available alternatives in the same drug class of immunomodulatory agents, lenalido-
mide (Revlimid) and pomalidomide (Pomalyst), are generally more efficacious and
less toxic than thalidomide.50–53 Therefore, the best thalidomide-based strategy for
seniors with MM is probably to consider avoiding the drug entirely by selecting a
different agent from the same class. In the uncommon circumstance that thalidomide
is required, caution is warranted. The toxicities of lenalidomide and pomalidomide are
primarily cytopenias, fatigue, and in some cases rash.50–53
High-dose corticosteroids, usually dexamethasone (Decadron) or prednisone, are
ubiquitous in MM regimens and for some patients are the most intolerable component
of therapy. The adoption of low-dose dexamethasone (usually once weekly) as the
standard for most regimens instead of the prior standard of high-dose dexametha-
sone (usually 4 days on, 4 days off) has mitigated steroid toxicity in MM54 but delirium,
insomnia, anxiety, weight gain caused by polyphagia, hyperglycemia, peripheral
edema, and peptic ulcers are still common. These toxicities can sometimes be
controlled through supportive care, but often remain difficult and dose reduction is
the safest course of action. Peptic ulcer disease prophylaxis is useful, because
many patients are on both dexamethasone and aspirin as part of their MM regimens
and both drugs predispose to ulcers and/or upper gastrointestinal bleeding.
Expert opinions regarding recommended starting doses for various drugs in MM
have been offered by our group as well as the European Myeloma Network in recent
years.55,56 More direct evidence is needed to further optimize treatment of older adults
with MM.
As for supportive care, older adults should also receive the same interventions as
younger patients with MM: herpes zoster prophylaxis with proteasome inhibitors
and thromboembolic prophylaxis with aspirin, or anticoagulation if additional risk fac-
tors for venous thromboembolism are present. Most patients with MM should receive
intravenous bisphosphonates given their capacity to reduce fractures and also pro-
long overall survival in MM.57 Before initiation of bisphosphonates, patients should
be evaluated by a dentist given the association between osteonecrosis of the jaw
(ONJ) and poor dentition. Major dental work (eg, extractions and implants) should
be avoided if possible in patients receiving intensive bisphosphonate therapy. Peripro-
cedural antibiotic prophylaxis has also been shown to reduce the risk of ONJ in obser-
vational studies. A recent set of guidelines covers this topic at length.58 Most patients
with MM but not hypercalcemia should take calcium and vitamin D supplementation
for bone health.59
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similar strategies using chemotherapy dose reductions/omissions, growth factors,
and/or transfusions can be used. Special attention should be paid to the combined ef-
fects of anemia, hypovolemia, and/or autonomic dysfunction to avoid orthostatic
hypotension, which can result in syncope or falls.
Because many older adults with MM die from their disease, palliative and hospice
care services are used frequently. Early palliative care involvement for patients with
challenging symptoms is important. Caregiver burden can be substantial in MM
because many patients are on complex treatment regimens, require frequent clinic
visits, and have difficulties coping with the illness.60 Providers need to be aware of
these issues and provide appropriate supportive services when needed and available.
SUMMARY
MM and MGUS are diseases of the elderly and frequently appear in the geriatrician’s
clinic. A keen awareness of signs or symptoms suggesting the presence of a plasma
cell disorder may prompt discovery of MM before the development of incapacitating
sequelae, such as pathologic fractures. Standard of care for MGUS and SMM is moni-
toring, whereas chemotherapy is standard for MM. Novel therapeutics and ASCT have
improved survival in MM but special caution is warranted when treating older adults
with MM because of the unique toxicity profiles of MM drugs, which can combine
with preexisting medical issues to produce adverse outcomes. Novel assessment
tools such as GA may facilitate the personalization of older patients’ MM treatment
programs in the future, maximizing the likelihood of MM control and minimizing the
risk of severe toxicity. Geriatricians are uniquely positioned to detect these diseases
early, support patients through treatment, and aid oncologists with an assessment
of the patient’s physiologic/functional age to provide optimal care for older adults
with these diseases.
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